Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
about
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsProspects of immune checkpoint modulators in the treatment of glioblastomaBRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.Recent advances and future of immunotherapy for glioblastoma.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.Special topics in immunotherapy and radiation therapy: reirradiation and palliationEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases.Embracing rejection: Immunologic trends in brain metastasis.The Microenvironmental Landscape of Brain Tumors.Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).Immune Checkpoint Inhibitors for Brain Metastases.Challenges in the delivery of therapies to melanoma brain metastases.Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.What have we learned from cancer immunotherapy in the last 3 years?Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma.Immune checkpoint inhibition in patients with brain metastases.Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.Innate and acquired immune surveillance in the postdissemination phase of metastasis.Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
P2860
Q26775546-302F0594-1028-4AC6-AA71-AC1405E423F1Q28081371-B532F215-3D7B-41D0-B565-44D6A9F42325Q34667825-1F4B76AB-9740-4746-987C-D8D7DF10A0ECQ35798996-578C924C-1ECD-48DD-A2CC-6F4EB700AA72Q35815273-BFE5BC24-7083-4FA9-8350-B519EC8AD157Q35820476-892FEF3C-5FFC-45FC-A34C-68DDCE9B00E2Q36028546-BCB59B05-E2B5-409F-8974-BD7EB82FF997Q36082506-9D74383B-8472-4342-B0B1-999EC2D8EF62Q37239071-DDBCC785-BE68-44F2-BD70-1A832D5F254DQ37584395-52CC61C2-3197-49C8-899F-62AB1FEBF177Q37606693-5E3F9BA8-B2C8-444C-8664-19E9661982C8Q37741143-9B3E6758-CDC9-482B-B585-4F8D14F2D2F2Q38771929-2E1B1F69-AC5E-4A2F-931A-BBB58B82CBDBQ38775281-A4B3FF46-EDC9-41D9-83A1-0A2C53C4B5F0Q38953017-2A1EE245-7182-4EF5-84A3-1D3B5C3B1D92Q39178065-6EFBCC09-DC9A-44A9-A3B5-16313915FFF4Q39229266-408BC912-15F8-49EB-8AD4-A1F98D756A7CQ39247421-3AF2CA48-EEB8-476D-BCBC-04103DAD799AQ39331752-CFC77B0A-AF9D-4BF7-A2D3-1F5BE0D4E0E6Q39688544-C4E5BA51-8927-4CB2-9480-3A207400C2A2Q40065733-E38502C1-6972-4B5C-8737-C7752630A4CFQ42049392-D65F2AE0-20AB-4F14-B4C0-2BE9E2A43A03Q42370384-73AB1CC7-27A1-46BE-86A0-CB4511318577Q46675575-2A68D36B-5C15-4BF0-8F7B-CFCC6E3FAA3AQ47825909-EF344579-8C11-4FDB-A29C-9F420E7FCCC0Q50048813-DA5DB0C0-4702-44CF-AA9E-DE037127C685Q50651030-EAF60B5A-63F6-439D-9AA5-F1DD5316021DQ55283310-B1FC52BE-8C77-4456-8715-1F913200DDCBQ57490955-607BF90D-C54D-4433-AFF2-4B19227138B8
P2860
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@ast
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@en
type
label
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@ast
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@en
prefLabel
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@ast
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@en
P2093
P2860
P50
P1476
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
@en
P2093
Alessandro Scoppola
Andrea Antonuzzo
Anna Maria Di Giacomo
Ester Simeone
Francesco Cognetti
Laura Ridolfi
Michele Guida
Paolo Antonio Ascierto
P2860
P2888
P304
P356
10.1007/S11060-014-1400-Y
P50
P577
2014-02-16T00:00:00Z
P5875
P6179
1048201517